Natco Pharma shares rise 4% ahead of board meeting to consider demerger plan
News by Aliceblue News Desk
20 Mar 2026
Introduction
Leading pharmaceutical company launches generic Semaglutide injection in India at affordable prices, offering multiple strengths and significantly lower costs compared to existing branded treatment options.
Also Read: HDFC Bank Chairman Quits Citing ‘Ethical’ Concerns, Shares Fall Over 4%
Share price movement of NATCO
On March 20, 2026, Natco Pharma Ltd opened at ₹941.75, up 0.50% from its previous close of ₹937.05. It reached a high of ₹973.00 (3.84%) and a low of ₹941.75. By 4:00 PM, it traded at ₹962.73, a 2.74% increase, with a market cap of ₹17,264.40 crore.
NATCO launches affordable generic Semaglutide in India
NATCO Pharma Limited announced launch of generic Semaglutide injection in India on patent expiry day after receiving CDSCO approval in February 2026 for multi dose vials and pen devices based.
NATCO will market multi dose vials in strengths 2mg 1.5ml 4mg 3ml and 8mg 3ml under SEMANAT and SEMAFULL brands with monthly prices starting at INR 1290 for Indian patients.
The company stated vials are about 70 percent cheaper than pen devices and 90 percent cheaper than innovator brands aiming to improve accessibility and long term treatment compliance for patients.
Stock performance of Natco Pharma for Period of 1 week, 6 months, and 1 year
Natco Pharma delivered a 1-week return of -1.86%, a 6-month return of 6.08%, and a 1-year return of 13.6%.
Also Read: Nazara Technologies stock in focus after ₹918 crore acquisition deal
Shareholding Pattern of Natco Pharma
| Particulars | Dec 2025 | Sep 2025 | Jun 2025 |
| Promoter | 49.50% | 49.50% | 49.60% |
| FII | 15.20% | 14.10% | 15.50% |
| DII | 5.40% | 5.90% | 5.80% |
| Public | 30.00% | 30.60% | 29.10% |
About Natco Pharma
Natco Pharma Ltd (NSE: NATCOPHARM) is a research-driven pharmaceutical company engaged in developing, manufacturing, and marketing formulations, APIs, and contract manufacturing across niche therapeutic segments.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
Q: Why is Natco Pharma share price rising today?
A: Natco Pharma share price is rising after announcing launch of affordable generic Semaglutide injection in India following patent expiry and CDSCO approval.
Q: What is Natco Pharma’s main business focus?
A: Natco Pharma main business focuses on developing, manufacturing, and marketing formulations, APIs, and contract manufacturing across niche therapeutic pharmaceutical segments.
Q: What are the 52-week high and low of Natco Pharma stock?
A: Natco Pharma stock has a 52-week high of ₹1,059.60 and a 52-week low of ₹660.05.
News Author
Aliceblue News Desk
